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tegarding Comparison of
ercutaneous Coronary
ntervention With Bare-Metal
nd Drug-Eluting Stents for
ardiac Allograft Vasculopathy
roblems With Listing Patients Receiving
lopidogrel for Re-Transplantation
read with interest the article entitled “Comparison of Percuta-
eous Coronary Intervention With Bare-Metal and Drug-Eluting
tents for Cardiac Allograft Vasculopathy” (1). This is an inter-
sting study showing a lower in-stent restenosis rate of patients
eceiving drug-eluting stents (DES) for allograft vasculopathy.
here are 2 major points that need clarification. The authors did
ot report any statistical analysis in regards to important end points
uch as death, myocardial infarction, or target vessel revasculariza-
ion in each group. We have to assume that these very important
nd points, including re-transplantation, were similar between the
roups. Death and re-transplantation occurred in 34% of the entire
ohort with follow-up of 1 year. This suggests poor prognosis of
atients with significant allograft vasculopathy, regardless of stent
ypes used. This is an important observation that needs to be
mphasized. The second important point concerns a major di-
emma that exists between interventional cardiologists and trans-
lant surgeons regarding duration of clopidogrel therapy after
oronary intervention for allograft vasculopathy. In our and many
enters, patients receiving clopidogrel therapy would not be listed
or re-transplantation due to theoretical risk for bleeding during
ardiac transplantation. Consequently, surgeons are proned to
arly discontinuation of clopidogrel therapy in patients treated
ith DES, putting them at risk for stent thrombosis. Therefore, it
s very important to discuss the choice of stent and duration of
lopidogrel therapy with surgeons for each individual patient
efore coronary intervention in the setting of allograft vasculopa-
hy. In patients who are not candidates for re-transplantation, the
se of a DES with prolonged dual antiplatelet therapy is probably
he best option. However, for younger patients who are candidates
or re-transplantation, the use of DES without consultation with
urgeons can lead to early discontinuation of dual antiplatelet
herapy or exclusion from retransplantation. It is important to note
hat clopidogrel does not increase mortality during coronary bypass
urgery (2,3). There are no data available evaluating the risk of
leeding or death in patients receiving clopidogrel therapy while
ndergoing cardiac transplantation.
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eply
e have read with interest the thoughtful response from Dr.
ovahed to our recent article entitled “Comparison of Percuta-
eous Coronary Intervention With Bare-Metal and Drug-Eluting
tents for Cardiac Allograft Vasculopathy” (1) and appreciate the
pportunity to address the points raised in the letter.
Our study indicates an advantage with the use of drug-eluting
tents (DES) compared with bare-metal stents (BMS) in terms of
ate lumen loss and rates of in-stent restenosis (ISR). More recent
ata support low rates of ISR when patients undergo percutaneous
oronary intervention (PCI) with DES for coronary artery vascu-
opathy (CAV) (2). Similarly, a study from Poland reported that
he use of DES was associated with a lower rate of ISR and longer
ime of freedom from ISR (3). Whereas other clinical end points
ere not reported for each group in our study, only 21% of all
atients underwent target vessel revascularization, indicating that
CI is a viable treatment option for patients with CAV. Although
ur study reports that 13% of the cohort patients underwent repeat
rthotopic heart transplantation (OHT) and 22% died, the mor-
ality rate was measured over the entire follow-up period. The 22%
ortality rate also included some patients who had undergone
epeat OHT, producing a lower combined rate of death and repeat
HT. Prospective randomized trials comparing DES with BMS
or CAV patients are needed to better ascertain clinical and
ngiographic outcomes with these modalities.
There is uncertainty regarding clopidogrel therapy in patients
ho are relisted for OHT and who have undergone PCI with DES
ithin 12 months. Premature discontinuation of dual antiplatelet
herapy after PCI with DES in patients who are relisted for OHT
ight increase the risk of stent thrombosis. Although the risk of
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475leeding might be increased if OHT is performed while patients
ontinue clopidogrel, our transplant surgeons have performed
HT on patients who continue clopidogrel and feel it is an
cceptable risk to operate on such patients, because the conse-
uences of stent thrombosis can be catastrophic. The case-fatality
ate of DES thrombosis is 45% (4). Studies examining outcomes of
atients receiving clopidogrel therapy undergoing OHT would
etermine the true bleeding risk of patients who undergo OHT
ith clopidogrel, the results of which would help clarify the
ptimal antiplatelet therapy in patients with DES who require
epeat OHT.
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